The gliptins are coming to dinner. And to breakfast and lunch.
The gliptins are a promising new class of drugs that block the enzyme known by the catchy name dipeptidyl peptidase 4 or DPP-4. They include two drugs, vildagliptin (proposed trade name Galvus) from the Swiss pharamaceutical giant Novartis and sitagliptin phosphate (proposed trade name Januvia) from an American company, Merck. [Read more →]